Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 20, 2023

Idroxioleic Acid: First-in-Class Sphingolipid Regulator and Glioma Cell Autophagy Inducer With Antitumor Activity in Patients With Refractory Glioma

British Journal of Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

British Journal of Cancer
A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma
Br. J. Cancer 2023 Jul 24;[EPub Ahead of Print], J Lopez, J Lai-Kwon, R Molife, L Welsh, N Tunariu, D Roda, P Fernández-García, V Lladó, AG McNicholl, CA Rosselló, RJ Taylor, A Azaro, J Rodón, J Sludden, GJ Veal, R Plummer, A Urruticoechea, A Lahuerta, K Mujika, PV Escribá

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.

Further Reading